Press Releases for the Psychedelics Industry

Psychedelics News

Press Releases

18 Jan 2021

Cybin Announces CDN$20 Million Bought Deal Offering

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES TORONTOJan....

By Microdose

Press Releases

18 Jan 2021

Havn Life to support Canadian counterpart of Veterans’ organization Heroic Hearts

Havn Life to grow its partnership with the US-based veterans’ organization by funding and supporting the launch of its Canadian counterpart....

By Microdose

Press Releases

14 Jan 2021

MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience

Psychedelic Pharmaceutical Scientist and Clinical Pharmacologist Robert Barrow Appointed as Chief Development Officer NEW YORKJan....

By Microdose

Press Releases

14 Jan 2021

Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin

TORONTO, Jan....

By Microdose

Join Our Newsletter for Exclusive Updates, Stories, and More

Press Releases

12 Jan 2021

MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers

MindMed to Commence Groundbreaking LSD Microdosing Study Evaluating Benefits on Neuroplasticity, Sleep, Cognitive Enhancement Variables and Immune System Response on the Human Body NEW YORKJan....

By Microdose

Press Releases

11 Jan 2021

Cybin Announces API Synthesis of Multiple Tryptamine Derivatives Based on the First Milestone Achievement Pursuant to the Adelia Acquisition

TORONTO, CANADA – January 11, 2021 – Cybin Inc....

By Microdose

Press Releases

11 Jan 2021

Cybin Partners with Kernel to Leverage its Breakthrough Neuroimaging Technology for Psychedelic Therapeutics

Using Kernel’s technology, Cybin will be able to quantify brain activity in real time during psychedelic experiences....

By Microdose

Press Releases

8 Jan 2021

COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care

COMPASS Pathways establishes Centre of Excellence with Sheppard Pratt to accelerate research and improve patient experience in mental health care Read more on Microdose...

By Microdose

Press Releases

7 Jan 2021

Field Trip Health Ltd. Announces Participation in a MAPS-sponsored Multi-Site Study of MDMA-Assisted Therapy to Treat Eating Disorders

TORONTO, Jan....

By Microdose

Follow us on social

Latest News

Trump’s Psychedelic Fast-Track Order Changes the Timeline. It Also Redraws the Competitive Map.

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result